RESUMO
Humans develop polyclonal, serotype-specific neutralizing antibody responses after dengue virus (DENV) infection. Many mouse antibodies that neutralize DENV bind to the lateral ridge or A strand epitopes on domain III of the viral envelope (EDIII) protein. It has been assumed that these epitopes are also the main target of human neutralizing antibodies. Using recombinant dengue serotype 2 viruses with altered EDIII epitopes, we demonstrate that EDIII epitopes are not the main target of human neutralizing antibody.
Assuntos
Anticorpos Neutralizantes/imunologia , Vírus da Dengue/imunologia , Dengue/imunologia , Epitopos/imunologia , Soros Imunes/imunologia , Proteínas do Envelope Viral/química , Proteínas do Envelope Viral/imunologia , Animais , Anticorpos Antivirais/imunologia , Dengue/virologia , Vírus da Dengue/química , Vírus da Dengue/genética , Epitopos/genética , Humanos , Camundongos , Estrutura Terciária de Proteína , Proteínas do Envelope Viral/genéticaRESUMO
Dengue viruses (DENVs), serotypes 1-4, are arthropod-borne viruses transmitted to humans by mosquitoes, primarily Aedes aegypti. The transmission cycle begins when Ae. aegypti ingest blood from a viremic human and the virus infects midgut epithelial cells. In studying viruses derived from the DENV2 infectious clone 30P-NBX, we found that when the virus was delivered to female Ae. aegypti in an infectious blood meal, the midgut infection rate (MIR) was very low. To determine if adaptive mutations in the DENV2 envelope (E) glycoprotein could be induced to increase the MIR, we serially passed 30P-NBX in Ae. aegypti midguts. After four passages, a single, non-conservative mutation in E protein domain II (DII) nucleotide position 1300 became dominant, resulting in replacement of positively-charged amino acid lysine (K) at position 122 with negatively-charged glutamic acid (E; K122E) and a significantly-enhanced MIR. Site directed mutagenesis experiments showed that reducing the positive charge of this surface-exposed region of the E protein DII correlated with improved Ae. aegypti midgut infection.
Assuntos
Aedes , Vírus da Dengue , Dengue , Animais , Vírus da Dengue/genética , Feminino , Humanos , SorogrupoRESUMO
The genetic stabilities of the three attenuation loci of the candidate dengue 2 (D2) PDK-53 vaccine virus were evaluated for the PDK-53 virus and PDK-53-vectored chimeric D2/1, D2/3, and D2/4 viruses following 10 sequential passages in Vero cells. Sequencing revealed that the dominant NS1-53-Asp and the NS3-250-Val attenuation loci were extremely stable, whereas reversion occurred at the 5'NCR-57-U locus in 10 of the 18 viral lineages tested. A more sensitive and quantitative assay, the TaqMan mismatch amplification mutation assay (TaqMAMA), was employed to more finely discriminate the level of reversion at the 5'NCR-57 locus. This rapid genetic assay permitted detection of
Assuntos
Vírus da Dengue/genética , Vírus Reordenados/genética , Vacinas Virais/genética , Animais , Antígenos Virais/genética , Chlorocebus aethiops , Instabilidade Genômica , Reação em Cadeia da Polimerase , RNA Helicases/genética , Análise de Sequência , Inoculações Seriadas , Serina Endopeptidases/genética , Vacinas Atenuadas/genética , Células Vero , Proteínas não Estruturais Virais/genéticaRESUMO
Chimeric dengue type 2/type 1 (DEN2/1) viruses, which contain the structural genes of the dengue-1 (16007) parental virus and the nonstructural genes of the DEN2-PDK53 virus, have been constructed. These DEN2/1 viruses induce high levels of DEN1 virus-specific neutralizing antibodies in mice. In this study, the DEN2/1 viruses induced DEN1 virus-specific neutralizing antibodies without the development of viremia in cynomolgus monkeys. Dengue virus-specific IgM antibodies were detected in the sera of the immunized animals as early as 3 days post-immunization. After challenge with the DEN1-16007 wild-type virus, only a low level of viremia was detected in chimeric DEN2/1 virus-immunized monkeys. A second challenge, with DEN2-16681 virus, was given while the levels of DEN2-specific neutralizing antibodies were very low: infectious Dengue 2 virus could not be detected in sera of the monkeys. A correlation between the level of neutralizing antibody and the incidence of viremia could not be found. In addition, there was no significant increase in the levels of interferon gamma and soluble interleukin 2 receptor in the sera of the challenged monkeys, which suggests a reduction in immunopathogenesis caused by T-cell activation. Our findings suggest that DEN2/1 viruses may used as a live-attenuated candidate vaccine because of their safety, broad immunogenicity, and lower immunopathogenicity.
Assuntos
Quimera , Vírus da Dengue/imunologia , Dengue/prevenção & controle , Vacinas Virais/imunologia , Animais , Anticorpos Antivirais/sangue , Vírus da Dengue/patogenicidade , Haplorrinos , Imunoglobulina M/sangue , Ativação Linfocitária , Macaca fascicularis , Testes de Neutralização , Vacinas Atenuadas , Viremia/prevenção & controleRESUMO
Using an infectious cDNA clone we engineered seven mutations in the putative heparan sulfate- and receptor-binding motifs of the envelope protein of dengue virus serotype 2, strain 16681. Four mutant viruses, KK122/123EE, E202K, G304K, and KKK305/307/310EEE, were recovered following transfection of C6/36 cells. A fifth mutant, KK291/295EE, was recovered from C6/36 cells with a compensatory E295V mutation. All mutants grew in and mediated fusion of virus-infected C6/36 cells, but three of the mutants, KK122/123EE, E202K, G304K, did not grow in Vero cells without further modification. Two Vero cell lethal mutants, KK291/295EV and KKK307/307/310EEE, failed to replicate in DC-SIGN-transformed Raji cells and did not react with monoclonal antibodies known to block DENV attachment to Vero cells. Additionally, both mutants were unable to initiate negative-strand vRNA synthesis in Vero cells by 72h post-infection, suggesting that the replication block occurred prior to virus-mediated membrane fusion.
Assuntos
Vírus da Dengue/fisiologia , Heparitina Sulfato/metabolismo , Proteínas do Envelope Viral/metabolismo , Internalização do Vírus , Animais , Sítios de Ligação , Linhagem Celular , Chlorocebus aethiops , Culicidae , Análise Mutacional de DNA , Proteínas Mutantes/genética , Proteínas Mutantes/metabolismo , Ligação Proteica , Proteínas do Envelope Viral/genéticaRESUMO
Fifteen mutant dengue viruses were engineered and used to identify AAs in the molecular hinge of the envelope protein that are critical to viral infection. Substitutions at Q52, A54, or E133 reduced infectivity in mammalian cells and altered the pH threshold of fusion. Mutations at F193, G266, I270, or G281 affected viral replication in mammalian and mosquito cells, but only I270W had reduced fusion activity. T280Y affected the pH threshold for fusion and reduced replication in C6/36 cells. Three different mutations at L135 were lethal in mammalian cells. Among them, L135G abrogated fusion and reduced replication in C6/36 cells, but only slightly reduced the mosquito infection rate. Conversely, L135W replicated well in C6/36 cells, but had the lowest mosquito infection rate. Possible interactions between hinge residues 52 and 277, or among 53, 135, 170, 186, 265, and 276 required for hinge function were discovered by sequence analysis to identify compensatory mutations.
Assuntos
Substituição de Aminoácidos , Vírus da Dengue/fisiologia , Dengue/virologia , Proteínas do Envelope Viral/genética , Internalização do Vírus , Aedes , Sequência de Aminoácidos , Animais , Linhagem Celular , Vírus da Dengue/química , Vírus da Dengue/genética , Humanos , Dados de Sequência Molecular , Mutação de Sentido Incorreto , Alinhamento de Sequência , Proteínas do Envelope Viral/química , Proteínas do Envelope Viral/metabolismo , Replicação ViralRESUMO
The FG extended loop in domain III of the dengue virus type 2 (DENV2) envelope protein is postulated to be a molecular determinant for host cell infectivity. To determine the contribution of the FG loop to virus infectivity, an infectious cDNA clone of DENV2 was manipulated by deleting amino acids in the loop (VEPGΔ) to mimic tick-borne flaviviruses or by substituting these AAs with RGD or RGDK/S to mimic motifs present in other mosquito-borne flaviviruses. We found the FG loop to be dispensable for infection of C6/36 cells but critical for infection of Aedes aegypti mosquito midguts and mammalian cells. All the FG loop mutants were able to bind to and enter mammalian cells but replication of VEPGΔ in Vero cells at 37 °C was delayed until acquisition of secondary mutations. Reduced binding of DENV2 type-specific monoclonal antibody 3H5 to mutant viruses confirmed the FG loop motif as its target epitope.
Assuntos
Aedes/virologia , Vírus da Dengue/fisiologia , Dengue/virologia , Proteínas do Envelope Viral/química , Proteínas do Envelope Viral/metabolismo , Sequência de Aminoácidos , Animais , Linhagem Celular , Chlorocebus aethiops , Vírus da Dengue/química , Vírus da Dengue/genética , Vírus da Dengue/crescimento & desenvolvimento , Células Hep G2 , Humanos , Dados de Sequência Molecular , Estrutura Terciária de Proteína , Células Vero , Proteínas do Envelope Viral/genética , Replicação ViralRESUMO
The flaviviral envelope (E) protein directs virus-mediated membrane fusion. To investigate membrane fusion as a requirement for virus growth, we introduced 27 unique mutations into the fusion peptide of an infectious cDNA clone of dengue 2 virus and recovered seven stable mutant viruses. The fusion efficiency of the mutants was impaired, demonstrating for the first time the requirement for specific FP AAs in optimal fusion. Mutant viruses exhibited different growth kinetics and/or genetic stabilities in different cell types and adult mosquitoes. Virus particles could be recovered following RNA transfection of cells with four lethal mutants; however, recovered viruses could not re-infect cells. These viruses could enter cells, but internalized virus appeared to be retained in endosomal compartments of infected cells, thus suggesting a fusion blockade. Mutations of the FP also resulted in reduced virus reactivity with flavivirus group-reactive antibodies, confirming earlier reports using virus-like particles.
Assuntos
Vírus da Dengue/fisiologia , Fusão de Membrana/fisiologia , Proteínas Virais de Fusão/fisiologia , Aedes/virologia , Animais , Antígenos Virais/imunologia , Linhagem Celular , Chlorocebus aethiops , Dengue/virologia , Vírus da Dengue/genética , Feminino , Mutagênese Sítio-Dirigida , Transfecção , Células Vero , Proteínas Virais de Fusão/genética , Replicação Viral/genética , Replicação Viral/fisiologiaRESUMO
Attenuation markers of the candidate dengue 2 (D2) PDK-53 vaccine virus are encoded by mutations that reside outside of the structural gene region of the genome. We engineered nine dengue virus chimeras containing the premembrane (prM) and envelope (E) genes of wild-type D1 16007, D3 16562, or D4 1036 virus within the genetic backgrounds of wild-type D2 16681 virus and the two genetic variants (PDK53-E and PDK53-V) of the D2 PDK-53 vaccine virus. Expression of the heterologous prM-E genes in the genetic backgrounds of the two D2 PDK-53 variants, but not that of wild-type D2 16681 virus, resulted in chimeric viruses that retained PDK-53 characteristic phenotypic markers of attenuation, including small plaque size and temperature sensitivity in LLC-MK(2) cells, limited replication in C6/36 cells, and lack of neurovirulence in newborn ICR mice. Chimeric D2/1, D2/3, and D2/4 viruses replicated efficiently in Vero cells and were immunogenic in AG129 mice. Chimeric D2/1 viruses protected adult AG129 mice against lethal D1 virus challenge. Two tetravalent virus formulations, comprised of either PDK53-E- or PDK53-V-vectored viruses, elicited neutralizing antibody titers in mice against all four dengue serotypes. These antibody titers were similar to the titers elicited by monovalent immunizations, suggesting that viral interference did not occur in recipients of the tetravalent formulations. The results of this study demonstrate that the unique attenuation loci of D2 PDK-53 virus make it an attractive vector for the development of live attenuated flavivirus vaccines.